- TRADE NAME: Epidiolex (GW Research Ltd)
- INDICATIONS: treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older
- SYNONYM: CBD
- HALF-LIFE: 56–61 hours
- FDA APPROVAL DATE: 06/25/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clobazam - PREGNANCY: may cause fetal harm
Please login to view the rest of this drug profile.
Page last updated 11/12/2023
